This site is intended for healthcare professionals

Phase III trial enrolling up to 30,000 adults aged 18 years or over to assess safety, efficacy and immunogenicity of AZD 1222 for the prevention of COVID-19.-AstraZeneca

Read time: 1 mins
Last updated:16th Mar 2021
Published:2nd Sep 2020
Condition: Coronavirus/COVID-19 Infection
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest